Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2009 Archives

Nov 24, 2009

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl...

More
Nov 16, 2009

Eisai Inc. today announced that LUSEDRA™ (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution,...

More
Nov 11, 2009
Eisai Employees, in Cooperation with the Foundation for Hospital Art, Create Artwork to Help Improve the Lives of Patients and Families

Eisai Inc. today announced that it has donated more than 80 pieces of artwork, created by its employees, to hospitals across the United States. The multi-panel murals were created by more than...

More
Oct 30, 2009
Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced...

More
Oct 29, 2009
2009 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care

Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award. (Photo: http://www.newscom.com/cgi-bin/prnh/20091029/NY00986

More
Oct 28, 2009

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody...

More
Sep 24, 2009

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced that it has reached a comprehensive agreement with Pfizer Inc. (Headquarters: New York, CEO and Chairman of...

More
Sep 24, 2009

Morphotek , Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in...

More
Sep 23, 2009

Morphotek , Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases...

More
Jul 15, 2009

Morphotek , Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology...

More
Jul 8, 2009

Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an...

More
Jul 2, 2009

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are...

More
Jul 1, 2009

Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic...

More
Jun 9, 2009
Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells

Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to study...

More
Jun 1, 2009
Eisai Inc. and the Alzheimer's Association Support Award to Recognize Critical Role of Pharmacists in Alzheimer's Care

Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2009 C.A.R.E....

More
 

print email rss